WeVote
Log In

Bill

Bill

HF 4034

Right to Try Act modified for individualized investigational treatments.

2025-2026 Regular Session Introduced by Jeff Dotseth

HF 4034 expands Minnesota's Right to Try Act to allow terminal patients faster access to individualized investigational treatments outside standard clinical trial pathways.

Introduction and first reading, referred to Health Finance and Policy
#healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · HF 4034

Legislative bill overview

HF 4034 modifies Minnesota's Right to Try Act to expand access to individualized investigational treatments for patients with terminal illnesses who have exhausted conventional treatment options. The bill appears to streamline or broaden the existing framework governing how patients can access experimental therapies outside of formal clinical trials.

Why is this important

Terminal patients often face limited options when approved treatments fail, and Right to Try laws address the ethical tension between regulatory caution and individual autonomy in end-of-life care. The modification could affect healthcare access, pharmaceutical company liability, physician liability, and how quickly patients can pursue experimental treatments.

Potential points of contention

  • Safety and efficacy standards: Expanding access to uninvestigated treatments raises questions about whether patient desperation could lead to ineffective or harmful outcomes, and how much safety data should be required
  • Liability and accountability: Clarifying who bears responsibility (patient, physician, manufacturer) if an experimental treatment causes harm or fails to help
  • Equity and cost: Whether patients can afford individualized treatments and whether insurance should cover experimental therapies, potentially creating disparities in access based on wealth

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.